UT Southwestern Center for Translational Medicine
UT Southwestern Center for Translational Medicine
批准号:
10614007
负责人:
Keith Edward Argenbright
金额:
$130.5万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-05-26 至 2026-04-30
关键词:
AcademyAccelerationAddressApplications GrantsAwardAwarenessBasic ScienceCareer ChoiceClinical ResearchCollaborationsCommunitiesCommunity HealthCompetenceCost SharingDevelopmentDimensionsDisciplineEducationEducational CurriculumElementsEnsureEvaluationExposure toFacultyFosteringFrequenciesFundingFutureGenderGenerationsGoalsGrantHealthHouse StaffsIncubatorsIndividualInformaticsInstitutionK-Series Research Career ProgramsManuscriptsMedicineMentorsMentorshipModelingModernizationPhysiciansProgram DevelopmentProgram EvaluationResearchResearch PersonnelResearch Project GrantsResearch TrainingResourcesRoleScholars ProgramScienceScientistSecureSeriesStructureTeam ProcessTechnologyTexasThinkingTrainingTraining ProgramsTraining and InfrastructureTranslational ResearchTranslationsVocational GuidanceWomancareercareer developmentcommunity engagementdesignempowermentethnic minorityexternshipimprovedinnovationinterdisciplinary collaborationpeerpeer coachingpre-clinical researchprogramsracial minorityrecruitsuccesstheoriestimelinetooltranslational engagementtranslational medicinetranslational pipeline
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The UT Southwestern Center for Translational Medicine's (CTM) KL2 Scholars Program already has a proven
track record for growing a new generation of Scholars who have become leaders in clinical and translational
research (CTR). Our KL2 program, with an ethos of continuous improvement based on metrics and changing
needs, has been a model of unique and centralized CTR training in our Hub. Our training curriculum has been
streamlined and modernized, and the diversity of our Scholars across all important domains has greatly
increased. In the new grant cycle, we will elevate our KL2 program to the next level through innovative
programming and cost sharing of CTSA, institutional and hub resources. We will appoint three new KL2
Scholars per year for a two-year term (ongoing total of six/year). KL2 Scholars will engage in mentored
research training, take formal coursework and short nanocourses on emerging CTR topics, and submit
manuscripts and grant proposals to secure individual career development and/or research grants (K2K and
K2R conversion, respectively) in a timely manner, to minimize the career-disrupting “K-cliff.” Careful program
evaluation will guide us to restructure elements further to increase the diversity of those we train and broaden
the disciplines and institutions from which the Scholars are recruited. The new KL2 plan proposed here is
significant and innovative. We will strategically leverage CTSA core and institutional resources to broaden
the KL2 program's impact and provide CTR training to an expanding pool of biomedical workforce. The four
Aims are integrated through our unique culturally-aware Tiered Mentorship Model, which includes
mentorship by primary and secondary research mentors, program directors, near-peer mentors, and Scholar
self-mentoring. We propose: Aim 1. Ensure personalized research career development, with customization
by a faculty-level Curriculum Navigator and a longitudinal training roadmap; Aim 2. Catalyze collaboration
and innovation by launching team science, community engagement, innovator studios and women in
technology programs; Aim 3. Promote K2R conversion to independent investigators by strengthening
longitudinal K2R progression along the K2R roadmap, creating an Interdiscipinary Sandwich Junior Mentor-in-
Training Program and a CTR-Scientific Management program to address unique needs of junior CTR PIs; Aim
4. Expand and strengthen the diverse CTR investigator pipeline by providing CTR training to existing
underrepresented trainee career development programs. Impact: Institutional resources will be leveraged to
expand the KL2's footprint and enlarge the CTR Scholar community. Rigorous evaluation metrics will be used
to enable us to improve our program iteratively. Our forward-thinking and integrated training paradigm will
greatly expand the number of Scholars armed with the tools for success and empowered to anticipate and
adapt effectively to become CTR leaders of the future.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
eGFR Trajectory in LVAD Recipients with Right Heart Failure: Status Quo or a Steady Decline?
患有右心衰竭的 LVAD 接受者的 eGFR 轨迹:现状还是稳步下降?
DOI:
10.1161/jaha.124.033925
发表时间:
2024
期刊:
Journal of the American Heart Association
影响因子:
5.4
作者:
[Roehm,Bethany, Agdamag,ArianneC]
通讯作者:
Agdamag,ArianneC
DOI:
10.1002/jmd2.12294
发表时间:
2022-09
期刊:
MOLECULAR GENETICS AND METABOLISM
影响因子:
3.8
作者:
[Goodspeed, Kimberly, Edgar, Veronica Bordes, Horton, Daniel, Lowden, Andrea, Sguina, Peter, Booth, Tim, Wang, Jerry]
通讯作者:
Wang, Jerry
DOI:
10.3390/genes13091655
发表时间:
2022-09-15
期刊:
Genes
影响因子:
3.5
作者:
[]
通讯作者:
Immune Dysregulation in Treatment-Resistant Depression: Precision Approaches to Treatment Selection and Development of Novel Treatments.
难治性抑郁症中的免疫失调:治疗选择和新疗法开发的精确方法。
DOI:
10.1016/j.psc.2023.02.010
发表时间:
2023
期刊:
The Psychiatric clinics of North America
影响因子:
--
作者:
[ChinFatt,CheriseR, Mayes,TarynL, Trivedi,MadhukarH]
通讯作者:
Trivedi,MadhukarH
DOI:
10.1038/s41598-022-24110-y
发表时间:
2022-12-01
期刊:
Scientific reports
影响因子:
4.6
作者:
[]
通讯作者:
共 19 条
UT Southwestern Center for Translational Medicine
-
批准号:10349047
-
项目类别:
-
资助金额:$130.63万
-
财政年份:2021
-
负责人:Keith Edward Argenbright
-
依托单位:
UT Southwestern Center for Translational Medicine
-
批准号:10412142
-
项目类别:
-
资助金额:$130.57万
-
财政年份:2021
-
负责人:Keith Edward Argenbright
-
依托单位:
海外基金